- Home
- GRI vs MSPR Comparison
GRI vs MSPR Comparison
Compare GRI & MSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- MSPR
- Stock Information
- Founded
- GRI 2018
- MSPR 2014
- Country
- GRI United States
- MSPR United States
- Employees
- GRI N/A
- MSPR N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- MSPR
- Sector
- GRI Health Care
- MSPR
- Exchange
- GRI Nasdaq
- MSPR NYSE
- Market Cap
- GRI 3.4M
- MSPR 4.8M
- IPO Year
- GRI N/A
- MSPR N/A
- Fundamental
- Price
- GRI $1.32
- MSPR $0.92
- Analyst Decision
- GRI Strong Buy
- MSPR
- Analyst Count
- GRI 2
- MSPR 0
- Target Price
- GRI $22.00
- MSPR N/A
- AVG Volume (30 Days)
- GRI 293.7K
- MSPR 424.4K
- Earning Date
- GRI 08-13-2025
- MSPR 08-13-2025
- Dividend Yield
- GRI N/A
- MSPR N/A
- EPS Growth
- GRI N/A
- MSPR N/A
- EPS
- GRI N/A
- MSPR N/A
- Revenue
- GRI N/A
- MSPR $13,085,000.00
- Revenue This Year
- GRI N/A
- MSPR N/A
- Revenue Next Year
- GRI N/A
- MSPR N/A
- P/E Ratio
- GRI N/A
- MSPR N/A
- Revenue Growth
- GRI N/A
- MSPR 34.74
- 52 Week Low
- GRI $1.10
- MSPR $0.87
- 52 Week High
- GRI $30.43
- MSPR $9.71
- Technical
- Relative Strength Index (RSI)
- GRI 38.24
- MSPR N/A
- Support Level
- GRI $1.93
- MSPR N/A
- Resistance Level
- GRI $2.20
- MSPR N/A
- Average True Range (ATR)
- GRI 0.20
- MSPR 0.00
- MACD
- GRI -0.07
- MSPR 0.00
- Stochastic Oscillator
- GRI 11.16
- MSPR 0.00
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About MSPR MSP RECOVERY INC
MSP Recovery Inc is a healthcare recovery and data analytics company. The business model includes two principal lines of business: Claims Recovery and Chase to Pay Services. It offers an antiquated healthcare reimbursement system with data-driven solutions to secure recoveries against responsible parties. MSP Recovery provides the healthcare industry with comprehensive compliance solutions platform to recover any claims where the law places primary payment responsibility on another payer.